Daily OTC Pearl: Sacubitril and Valsartan (Entresto)

Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure.

Medication Pearl of the Day: Sacubitril and Valsartan (Entresto)

Indication: Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction below normal.

Insight:

  • Dosing: Initiate low dose and increase to higher dose every 2 weeks.
  • Dosage forms: Film-coated tablets 24/26 mg; 49/51 mg; 97/103 mg.
  • Adverse events: Adverse reactions occurring ≥ 5% are hypotension, hyperkalemia, cough, dizziness, and renal failure.
  • Mechanism of action: Entresto contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. Entresto inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 receptor via valsartan.

Source: entresto.pdf (novartis.us)